Background: The association between peroxisome proliferators-activated receptor γ (PPARγ) Pro12Ala polymorphism and T2DN risk is inconclusive and contradictory. Therefore, we performed a meta-analysis.
Methods: All relevant studies were searched by using the PubMed and EMBASE. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated. Effect model selection was on the basis of heterogeneity test.
Results: A total of 20 case-control studies with 9357 subjects were included in this meta-analysis. We found that PPARγ Pro12Ala polymorphism significantly associated with decreased T2DN risk (OR = 0.74; 95% CI 0.59-0.94; P = 0.01). In the subgroup analysis by race, Caucasian with PPARγ Pro12Ala polymorphism showed decreased T2DN risk (OR = 0.63; 95% CI 0.46-0.88; P = 0.006). But Asian with PPARγ Pro12Ala polymorphism did not show decreased T2DN risk (OR = 0.87; 95% CI 0.62-1.22; P = 0.41).
Conclusions: In conclusion, our meta-analysis study confirmed that PPARγ Pro12Ala polymorphism might contribute to the risk for T2DN.
Keywords: Diabetic nephropathy; peroxisome proliferators-activated receptor γ; polymorphism.